NEW YORK (GenomeWeb News) — CombiMatrix today said that fourth-quarter revenue plunged 76 percent as R&D spending jumped 24 percent and net loss widened 150 percent.
 
The company also said it has named Mansoor Mohammed to be CEO of CombiMatrix subsidiary CombiMatrix Molecular Diagnostics, replacing Matt Watson, who stepped down to “pursue other opportunities.” Mohammed had been president and COO of CMDX.
 
CMDX said Watson will remain a consultant to the company for three months.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.